Prognostic significance of inflammation in patients with coronary artery disease at low residual inflammatory risk.
Cardiovascular medicine
Death
Pathophysiology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
received:
21
05
2023
revised:
02
09
2023
accepted:
22
09
2023
medline:
9
11
2023
pubmed:
9
11
2023
entrez:
9
11
2023
Statut:
epublish
Résumé
Patients with coronary artery disease (CAD) at low residual inflammatory risk are often overlooked in research and practice. This study examined the associations between fourteen inflammatory indicators and all-cause mortality in 5,339 CAD patients with baseline high-sensitivity C-reactive protein (hsCRP) <2 mg/L who received percutaneous coronary intervention and statin and aspirin therapy. The median follow-up time was 2.1 years. Neutrophil-derived systemic inflammatory response index (SIRI) yielded the strongest and most robust association with all-cause mortality among all indicators. Lower hsCRP remained to be associated with a lower risk of all-cause mortality. A newly developed comprehensive inflammation score (CIS) showed better predictive performance than other indicators, which was validated by an independent external cohort. In conclusion, neutrophil-derived indicators, particularly SIRI, strongly predicted all-cause mortality independent of hsCRP in CAD patients at low residual inflammatory risk. CIS may help identify individuals with inflammation burdens that cannot be explained by hsCRP alone.
Identifiants
pubmed: 37942015
doi: 10.1016/j.isci.2023.108060
pii: S2589-0042(23)02137-5
pmc: PMC10628835
doi:
Types de publication
Journal Article
Langues
eng
Pagination
108060Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Eur J Intern Med. 2022 Aug;102:24-39
pubmed: 35537999
Lancet. 2018 Jan 27;391(10118):319-328
pubmed: 29146124
N Engl J Med. 2019 Dec 26;381(26):2497-2505
pubmed: 31733140
Eur Heart J. 2021 Mar 1;42(9):896-903
pubmed: 33417682
Eur Heart J. 2022 May 14;43(19):1799-1808
pubmed: 35567558
J Am Coll Cardiol. 2019 May 21;73(19):2401-2409
pubmed: 31097159
N Engl J Med. 2020 Nov 5;383(19):1838-1847
pubmed: 32865380
N Engl J Med. 2005 Jan 6;352(1):20-8
pubmed: 15635109
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Platelets. 2015;26(7):680-1
pubmed: 25549287
Eur Heart J. 2022 Apr 19;43(16):1569-1577
pubmed: 35139537
N Engl J Med. 2019 Feb 21;380(8):752-762
pubmed: 30415610
Ann Med. 2022 Dec;54(1):1667-1677
pubmed: 35695557
JAMA Cardiol. 2023 Feb 1;8(2):177-181
pubmed: 36449307
J Atheroscler Thromb. 2022 Nov 1;29(11):1634-1645
pubmed: 35013023
Int Heart J. 2020 May 30;61(3):447-453
pubmed: 32418963
J Inflamm Res. 2021 Jan 18;14:131-140
pubmed: 33500649
Int J Mol Sci. 2021 Aug 24;22(17):
pubmed: 34502027
JACC Asia. 2022 Apr 12;2(3):323-337
pubmed: 36338415
Circulation. 2018 Jul 10;138(2):131-140
pubmed: 29530884
J Inflamm Res. 2022 Sep 07;15:5141-5156
pubmed: 36105384
Circulation. 2020 Nov 17;142(20):1996-1998
pubmed: 32864998
Eur Heart J. 2018 Dec 7;39(46):4101-4108
pubmed: 30358832
Cells. 2022 Mar 26;11(7):
pubmed: 35406687
Nihon Geka Gakkai Zasshi. 1984 Sep;85(9):1001-5
pubmed: 6438478
Int J Mol Sci. 2022 Aug 23;23(17):
pubmed: 36076952
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029621999717
pubmed: 33749340
Cardiovasc Res. 2022 Sep 20;118(12):2596-2609
pubmed: 34534269